Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of Sulthiame in Participants With Renal Impairment
NCT07857837Phase 1Not yet recruiting
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Sep 2026
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 1, open-label trial of SASS-002 (3 arms), sponsored by Shionogi & Co., Ltd. Primary endpoints: Maximum Observed Plasma Concentration, Time to Reach Cmax and 4 more. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
SASS-002
Beyond the preview
Go deeper on NCT07857837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07857837.